related kinases

& human disease conference

Saint-Malo, France
November 22-26, 2022

General information

General presentation

All major physiological phenomena are regulated by protein phosphorylation which is catalysed by protein kinases. Many diseases are associated with abnormal phosphorylation. Consequently, the last four decades have seen considerable efforts in the study of function and regulation of protein kinases in essentially all aspects of biology. In parallel, pharmacological inhibitors of kinases have become a major R&D area for the pharmaceutical industry in its search for new therapies. As of early 2020, 49 kinase inhibitors have reached the pharmaceutical market.

DYRKs (‘dual specificity, tyrosine phosphorylation regulated kinase 1’) (DYRK1A, 1B, 2, 3, 4) play key roles in mRNA splicing, chromatin transcription, DNA damage repair, cell survival, cell cycle, differentiation, endocytosis, neuronal development and functions, synaptic plasticity, folate and methionine metabolism. Inhibition of DYRKs may find applications in Down syndrome, Alzheimer’s disease and tauopathies, Parkinson’s disease, CDKL5 Deficiency Disorder diabetes, osteoarthritis, viral infections and various cancers. The closely related CLKs (‘cdc2-like kinases) (CLK1, 2, 3, 4) also play essential functions in Alzheimer’s disease and tauopathies, alternative splicing, various viral infections, cancers, body temperature sensing. DYRK and CLK orthologs are found in plants, yeast and unicellular parasites.


The conference will focus on DYRK1A and related kinases, including structural, regulatory and functional aspects, substrates and interactors, functions at cell and organism levels as well as development and potential therapeutic use of selective pharmacological inhibitors.


Palais du Grand Large, St Malo, Bretagne, France



Scientific information


Laurent MEIJER

Perha Pharmaceuthicals,

Roscoff, France


Masatoshi HAGIWARA

Department of Anatomy

& Developmental Biology,

Graduate School of Medicine,

Kyoto University, Kyoto, Japan


Peter P. DE DEYN

Department of Neurology,

General Hospital Middelheim and Institute Born-Bunge University of Antwerp,

Antwerpen, Belgium


Mariona ARBONES, Barcelona, Spain

          Control of neuron numbers by DYRK1A: lessons from mouse models


Walter BECKER, Aachen, Germany

          DYRK1B – a cancer drug target?


Thierry BESSON, Rouen, France

          Novel DYRKs/CLKs inhibitors


Mara DIERSSEN, Barcelona, Spain

          Clinical trials with EGCG, PERSEUS trial


Peter DE DEYN, Antwerpen, Belgium

          Down syndrome, Alzheimer’s disease & DYRK1A


Susana DE LA LUNA, Barcelona, Spain

          DYRK1A & DNA damage


Masatoshi HAGIWARA, Kyoto, Japan

          Development of inhibitors of CLK1 and DYRK1A, and their clinical applications


Yann HERAULT, Strasbourg, France

          The role of DYRK1A dosage in Down syndrome deficits


Florian HEYD, Berlin, Germany

          CLK in body temperature cycles


Nathalie JANEL, Paris, France

          DYRK1A interactants, a link between Down's syndrome and Alzheimer’s disease

Stefan KNAPP, Frankfurt, Germany

          Selective targeting of kinases regulation RNA splicing


Akiko KOBAYASHI, Kyoto, Japan

          Neuroprotection through suppression of inflammation by DYRK inhibitors


Conrad KUNICK, Braunschweig, Germany

          New DYRK1B inhibitors


Laurent MEIJER, Roscoff, France

          Leucettinibs, a second-generation family of DYRKs/CLKs inhibitors: from natural products to clinical


Lenka MUNOZ, Sydney, Australia

          Phosphoproteomic screen in cells upon DYRK1A inhibition: identification of new DYRK1A down-stream



William M. OLD, Boulder & Aurora, USA

          Revealing new functions of DYRK1A through interactome and substrate profiling


Sang Ki PARK, Pohang, Korea

          Sequential phosphorylation of NDEL1 by the DYRK2-GSK3β complex is critical for neuronal



Lucas PELKMANS, Zurich, Switzerland

          Kinase-controlled phase transition of membrane-less organelles in mitosis


Amélie PITON, Illkirch, France

          DYRK1A, a gene frequently mutated in intellectual disability

Randall J. ROPER, Indianapolis, USA

          DYRK1A and skeletal deficits associated with Down syndrome


Andrew F. STEWART, New York, USA

          DYRK1A inhibitors for beta cell proliferation to treat diabetes

Invited speakers (tentative titles)

The final program will be available in October 2022.

Abstract submission

Organization: Arial 11, 1 page maximum, title (bold), authors (underline presenting author), addresse-mail contactabstract, 1-3 compact references, (funding). Save under ‘yourname.doc’ or ‘yourname.docx’.

Submit abstract as an attached Word document, through the Conference e-mail address                                   (dyrk-conference@perha-pharma.com), with your name as ‘subject’.

Abstract submission deadline: September 30, 2022.


Instructions for speakers

There will be no poster sessions. We will try to have as many people as possible, especially students and post-docs, presenting their results. Besides invited speakers, submitted abstracts will be selected for long (15 min) or short (5 min) oral presentations (+ 5 min discussion).

Call for authors

We plan to put together an open-access e-book collating articles on the conference topic. It will be published by Frontiers in Neurology (www.frontiersin.org). Contribution to this e-book will be open to everyone, whether attending or not to the conference. The plan is to have the final e-book ready by the opening of the conference. Please consider this opportunity. More information will be sent to the DYRKs/CLKs community in the coming months.



Travel grants for young researchers

The « Fondation Vaincre Alzheimer » is open to receive travel grant applications from young researchers.  Do not hesitate to submit your application at: https://www.vaincrealzheimer.org/espace-chercheur-bourse-voyage/

Getting to Saint-Malo

The easiest: Fast train (TGV) from Paris-Montparnasse train station.

Please consult our information for international access here.

Saint-Malo & Brittany

Tourism office: www.saint-malo-tourisme.com

Saint-Malo city hall: www.ville-saint-malo.fr


& Accommodation

Important dates

Very early bird registration deadline: July 31, 2022.

Early bird registration deadline: September 4, 2022.

Late registration: September 4 up to October 31, 2022.

Start of the conference: November 22, 2022 at 17:00.

End of the conference: November 26, 2022 at 12:00.

Registration cost

Registration comprises access to all conferences, program, coffee/tea breaks and lunches.


Very early bird registration deadline:

Industry: 600 €                        Academy: 500 €                      PhD Students*: 300 €.

Early bird registration deadline:

Industry: 800 €                        Academy: 600 €                      PhD Students*: 400 €.

Late registration:

Industry: 1000 €                      Academy: 700 €.                     PhD Students*: 500 €.

                                                                                                 * Photocopy of student card required


Please consult our list of accommodation here.



& Exhibitions

Click on the logo to access the site.

Vaincre Alzheimer.png
Campus de la Mer.png
J.Lejeune logo.png
T21RS ok.png